Cecilia Pessoa Gingerich

Rizaport is an oral film formulation of rizatriptan benzoate, the active drug in Maxalt, for patients with migraine who experience dysphagia or migraine-related nausea.

Aimmune’s Biologics License Application for AR101 under evaluation as a treatment to reduce the risk of anaphylaxis in peanut-allergic children and adolescents following exposure to peanut.

A large retrospective study of patients with acne found no significant association between isotretinoin exposure and depression.

Continued consumption of peanuts was associated with positive quality of life and perceptions of safety following immunotherapy treatment for peanut allergy.

A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.

Topical medical grade cannabis ointment found to be safe and tolerable in early trial for skin disease.

Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Onasemnogene abeparvovec (Zolgensma) is a 1-time infusion that replaces the defective or missing SMN1 gene with a functional copy.

Safety data came from both phase 3 studies as well as a phase 2 study of Dextenza, which together totaled 351 patients.

Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.

Fingolimod (Gilenya) found to significantly reduce the annualized relapse rate compared with glatiramer acetate among patients with relapsing-remitting multiple sclerosis.

New 5-year data from phase 3 studies show that patients treated earlier with ocrelizumab (Ocrevus) had better outcomes on multiple measures of multiple sclerosis disease activity.

Siponimod is an oral, once-daily medication for the treatment of multiple sclerosis in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

The FDA approved cenegermin (Oxervate), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea.

Newly published research shows that from 2007 to 2016 opioid prescriptions have remained relatively unchanged, despite the growing awareness of potential dangers of opioid abuse.

The phase 3 CAPSTONE-2 study of the safety and efficacy of baloxavir marboxil in patients at high risk of complications due to influenza (flu) has met the primary objective of efficacy of a single dose of baloxavir marboxil compared to placebo.

Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).

The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.

The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA.

Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.

Emicizumab-kxwh is an antibody that activates the natural coagulation process in people with hemophilia A who lack factor VIII.

Sanofi announced that the FDA has accepted the New Drug Application (NDA) for Zynquista (sotagliflozin).

Burosumab (Crysvita, Ultragenyx) is the first treatment approved for x-linked hypophosphatemia in adults and children ages 1 and older.

AVXS-101 gene therapy for the treatment of children with spinal muscular atrophy type 1 showed remarkable progress, especially for children treated at less than 3 months of age.

Galcanezumab shows a significant reduction in monthly migraine days in treatment-resistant patients.

The serious condition leaves children with bowed legs, short stature, and bone and dental pain.

The ProGlide delivers a single suture to close puncture sites in the femoral vein or artery following a catheterization procedure.

Drug overdoses killed 63,632 Americans in 2016 and nearly 66% of those deaths involved a prescription or illicit opioid.